Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × talazoparib × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

pembrolizumab 42 Specimen Handling 35 Biopsy 32 Magnetic Resonance Spectroscopy 31 Cisplatin 27 Carboplatin 27 Cyclophosphamide 23 Paclitaxel 20 Nivolumab 18 Gemcitabine 17 Doxorubicin 17 durvalumab 16 Radiotherapy 15 Rituximab 14 Radiation 14 Prednisone 14 olaparib 13 Pemetrexed 13 Lenalidomide 12 fludarabine 11 Radiotherapy, Intensity-Modulated 11 Ipilimumab 11 Fulvestrant 11 Fluorouracil 11 Disulfides 11 Bevacizumab 11 Vincristine 10 Immunoglobulin G 10 Docetaxel 10 1,2-diaminocyclohexaneplatinum II citrate 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡